When Medicxi closed its third investment fund – €400 million Medicxi III, in just six weeks, Instinctif Partners was called upon to swing into action quickly to develop a media strategy to unveil the new fund drive interest from ambitious scientific entrepreneurs and drug hunters looking for investment.
Medicxi is a leading international life sciences focused investment firm and Medicxi III brings the total funds raised by Medicxi in the last three years to over $1 billion.
We developed key messages, Q&A and press release that ensured that Medicxi’s investment strategy across the full healthcare continuum, from discovery to late stage clinical assets, was understood, and that Novartis and Johnson & Johnson Innovation – JJDC, Inc. were returning cornerstone investors, together all past financial investors. Also that some significant new investors included established hospital foundations and medical institutions.
Our media strategy focused on briefing top tier media influencers under embargo, drawing out the key messages and Medicxi’s impress track record were communicated.
Impact on announcement day was maximised by the print, online and social media coverage achieved through the media targeted under embargo including Financial Times, Bloomberg, Scrip, Biocentury, Endpoints, Fierce, Bioworld, Labiotech and Mednous.
Follow up after the announcement was released on Businesswire and to additional media led to wide spread coverage across life science and pharma business press as well as venture and private equity media.